Neuland Laboratories Limited — Updates, 10-02-2025: Press Release

**Financial Highlights:** Neuland Laboratories reported total income of Rs. 401.9 crore for Q3FY25, reflecting a year-on-year growth of 1.8% from Rs. 394.9 crore in Q3FY24. However, EBITDA significantly decreased to Rs. 90.3 crore, down 26.4%, leading to an EBITDA margin of 22.5%, a decline of 860 bps. The PAT improved to Rs. 101.4 crore, up 25.6% YoY, and a remarkable increase of 217.3% QoQ.

**Strategic Initiatives and Growth Drivers:** The company maintains a positive outlook, driven by growth in its commercial CMS and GDS segments, with expectations for new molecules to further boost revenues. Neuland is focused on expanding manufacturing capacity and refining processes to enhance customer acquisition and retention.

**Business Developments:** Recent traction from existing customers and interest from new clients, particularly in peptides, prompted Neuland to invest in increased capacity. This strategic move aims to capitalize on the growing demand in these areas.

**Market Position and Competitive Advantage:** Neuland's established reputation as a reliable API manufacturer positions it favorably within a competitive landscape. Its cGMP certifications and diverse product offerings are key competitive advantages.

**Investor Implications:** The mixed financial results suggest caution, but the strategic investments and anticipated growth in demand for APIs provide an opportunity for positive long-term returns. Investors should watch for execution on capacity expansions and the company's ability to sustain growth momentum.